{{Rsnum
|rsid=6162
|Gene=CYP17A1
|Chromosome=10
|position=104596981
|Orientation=plus
|GMAF=0.4288
|Gene_s=CYP17A1
|Assembly=GRCh37.p5
|GenomeBuild=37.3
|dbSNPBuild=137
|geno1=(A;A)
|geno2=(A;G)
|geno3=(G;G)
}}
{{ population diversity
| geno1=(A;A)
| geno2=(A;G)
| geno3=(G;G)
| CEU | 18.5 | 46.2 | 35.4
| HCB | 28.9 | 51.1 | 20.0
| JPT | 11.4 | 52.3 | 36.4
| YRI | 11.1 | 30.2 | 58.7
| ASW | 0.0 | 0.0 | 0.0
| CHB | 28.9 | 51.1 | 20.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PMID Auto
|PMID=23186779
|Title=Molecular markers in Key Steroidogenic Pathways, Circulating steroid levels and Prostate Cancer progression
}}

{{PMID Auto
|PMID=18163429
|Title=Genetic polymorphisms in CYP17, CYP3A4, CYP19A1, SRD5A2, IGF-1, and IGFBP-3 and prostate cancer risk in African-American men: the Flint Men's Health Study.
|OA=1
}}

{{PMID Auto
|PMID=20411041
|Title=Common Variation in the CYP17A1 and IFIT1 Genes on Chromosome 10 Does Not Contribute to the Risk of Endometriosis.
|OA=1
}}

{{PMID Auto
|PMID=21656827
|Title=CYP17 gene polymorphisms and prostate cancer risk: a meta-analysis based on 38 independent studies.
}}

{{PMID Auto
|PMID=22714708
|Title=Genetic polymorphisms of CYP17A1 in steroidogenesis pathway are associated with risk of progression to castration-resistant prostate cancer in Japanese men receiving androgen deprivation therapy.
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}